Merck's Keytruda Marches On In Melanoma With NICE Nod
This article was originally published in Scrip
Merck & Co. Inc.'s PD-1 inhibitor Keytruda (pembrolizumab) has been given the provisional green light from the British national health technology association NICE as a treatment for some patients with advanced melanoma which is either inoperable or metastatic – provided the US drug maker makes the immune-oncology therapy available at an agreed discounted price.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.